Applied DNA Sciences (APDN) 10-Q 9 Feb 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Dec. 31, 2014	Feb. 02, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	APPLIED DNA SCIENCES INC
Entity Central Index Key	744452
Trading Symbol	apdn
Current Fiscal Year End Date	-21
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		17,361,702
Document Type	10-Q
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Sep. 30, 2014
Current assets:
Cash and cash equivalents	$2,871,570	$1,393,132
Accounts receivable, net of allowance of $11,257 and $9,634 at December 31, 2014 and September 30, 2014, respectively	1,114,541	834,818
Prepaid expenses	149,117	135,365
Total current assets	4,135,228	2,363,315
Property, plant and equipment, net of accumulated depreciation of $845,357 at December 31, 2014 and $759,087 at September 30, 2014	520,682	576,128
Other assets:
Deposits	61,988	57,638
Deferred offering costs		181,104
Intangible assets:
Intellectual property, net of accumulated amortization and impairment of $279,664 and $256,208 at December 31, 2014 and September 30, 2014, respectively	304,416	327,872
Total Assets	5,022,314	3,506,057
Current liabilities:
Accounts payable and accrued liabilities, including related party accrued interest of $-- and $6,597 at December 31, 2014 and September 30, 2014, respectively	1,197,012	1,494,759
Promissory notes payable, including $1,000,000 with a related party		1,800,000
Deferred revenue	524,361	583,362
Total current liabilities	1,721,373	3,878,121
Warrant liability		1,096,412
Total liabilities	1,721,373	4,974,533
Commitments and contingencies (Note I)
Stockholders' Equity (Deficit)
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of December 31, 2014 and September 30, 2014
Common stock, par value $0.001 per share; 500,000,000 and 1,350,000,000 shares authorized; 17,361,702 and 13,935,954 shares issued and outstanding as of December 31, 2014 and September 30, 2014, respectively	17,362	13,937
Additional paid in capital	210,872,495	198,277,859
Accumulated deficit	-207,588,916	-199,760,272
Total stockholders' equity (deficit)	3,300,941	-1,468,476
Total Liabilities and Stockholders' Equity (Deficit)	5,022,314	3,506,057
Series A Preferred stock
Stockholders' Equity (Deficit)
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of December 31, 2014 and September 30, 2014
Series B Preferred stock
Stockholders' Equity (Deficit)
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of December 31, 2014 and September 30, 2014

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Dec. 31, 2014	Sep. 30, 2014
Allowance on accounts receivable (in dollars)	$11,257	$9,634
Accumulated depreciation on property, plant and equipment (in dollars)	845,357	759,087
Accumulated amortization and impairment on intellectual property (in dollars)	279,664	256,208
Related party accrued interest (in dollars)		6,597
Promissory note issued to related party (in dollars)		$1,000,000
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	500,000,000	1,350,000,000
Common stock, shares issued	17,361,702	13,935,954
Common stock, shares outstanding	17,361,702	13,935,954
Series A Preferred stock
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Preferred stock
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Revenues	$1,241,802	$597,354
Operating expenses:
Selling, general and administrative	4,671,490	3,845,578
Research and development	278,288	459,304
Depreciation and amortization	109,726	105,215
Total operating expenses	5,059,504	4,410,097
LOSS FROM OPERATIONS	-3,817,702	-3,812,743
Other income (expense):
Interest income (expense), net	-31,875	434
Other income (expense), net	-3,685	155,417
Loss on conversion of promissory notes	-980,842
Loss on change in fair value of warrant liability	-2,994,540	-2,634,758
Net loss before provision for income taxes	-7,828,644	-6,291,650
Provision for income taxes
NET LOSS	($7,828,644)	($6,291,650)
Net loss per share-basic and diluted (in dollars per share)	($0.51)	($0.48)
Weighted average shares outstanding-
Basic and diluted (in shares)	15,456,566	13,164,914

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	($7,828,644)	($6,291,650)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	109,726	105,215
Stock based compensation expense	1,998,524	765,546
Change in fair value of warrant liability	2,994,540	2,634,758
Loss on conversion of promissory notes	980,842
Common stock issued for consulting services		337,500
Bad debt expense	2,779	15,000
Change in operating assets and liabilities:
Accounts receivable	-282,502	-91,716
Prepaid expenses and deposits	-18,102	47,686
Accounts payable and accrued liabilities	-253,997	234,728
Deferred revenue	-59,001	176,485
Net cash used in operating activities	-2,355,835	-2,066,448
Cash flows used in investing activities:
Purchase of property plant and equipment	-30,825	-94,510
Net cash used in investing activities	-30,825	-94,510
Cash flows from financing activities:
Net proceeds from sale of common stock and warrants	7,956,050
Purchase and cancelation of previously issued warrants	-4,090,952
Net cash provided by financing activities	3,865,098
Net increase (decrease) in cash and cash equivalents	1,478,438	-2,160,958
Cash and cash equivalents at beginning of period	1,393,132	6,360,301
Cash and cash equivalents at end of period	2,871,570	4,199,343
Supplemental Disclosures of Cash Flow Information:
Cash paid during period for interest
Cash paid during period for taxes
Non-cash investing and financing activities:
Common stock issued for cashless exercise of options and warrants		18,823
Reclassification of deferred offering costs in connection with underwritten public offering	181,104
Property, plant and equipment acquired, and included in accounts payable		$8,269

SUMMARY_OF_ACCOUNTING_POLICIES

SUMMARY OF ACCOUNTING POLICIES	3 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
SUMMARY OF ACCOUNTING POLICIES	NOTE A — SUMMARY OF ACCOUNTING POLICIES
	General
	The accompanying condensed consolidated financial statements as of December 31, 2014 and for the three month periods ended December 31, 2014 and 2013 are unaudited. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Rule S-X of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements.
	In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three month period ended December 31, 2014 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2015. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended September 30, 2014 and footnotes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC.
	The condensed consolidated balance sheet as of September 30, 2014 contained herein has been derived from the audited consolidated financial statements as of September 30, 2014, but do not include all disclosures required by GAAP.
	All warrant, option, share, and per share information in the condensed consolidated financial statements gives retroactive effect to the one-for-60 reverse stock split that was effected on October 29, 2014. See Note G.
	Business and Basis of Presentation
	On September 16, 2002, Applied DNA Sciences, Inc. (the “Company”) was incorporated under the laws of the State of Nevada. Effective December 17, 2008, the Company reincorporated from the State of Nevada to the State of Delaware. The Company is principally devoted to developing DNA embedded biotechnology security solutions in the United States and Europe. To date, the Company has had a limited operating history, and as a result, its operations have produced limited recurring revenues from its services and products; it has incurred expenses and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a biotechnology company. For the period from inception through December 31, 2014, the Company has accumulated losses of $207,588,916.
	The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, APDN (B.V.I.) Inc. and Applied DNA Sciences Europe Limited, which currently have no operations or activity. Significant inter-company transactions and balances have been eliminated in consolidation.
	Revenue Recognition
	The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered or services provided and the collectability of those amounts. Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered, service has not been provided, or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered, the service has been provided, or no refund will be required. At December 31, 2014 and September 30, 2014, the Company recorded deferred revenue of $524,361 and $583,362, respectively.
	Revenue arrangements with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered component has stand-alone value to the customer. Consideration received is allocated among the separate units of accounting based on their respective selling prices. The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party is available. The applicable revenue recognition criteria are then applied to each of the units.
	Revenue for government contract awards, which supports the Company’s development efforts on specific projects, is recognized as milestones are achieved as per the contract. The Company recognized revenue of approximately $449,647 and $25,000 from these contract awards during the three month periods ended December 31, 2014 and 2013, respectively.
	Net Loss Per Share
	The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share. Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants.
	For the three month periods ended December 31, 2014 and 2013, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.
	Securities that could potentially dilute basic net income per share in the future that were not included in the computation of diluted net loss per share because to do so would have been antidilutive for the three month periods ended December 31, 2014 and 2013 are as follows:
		2014		2013
	Warrants		4,470,502		688,969
	Employee options		3,777,888		3,166,416
			8,248,390		3,855,385
	Stock Based Compensation
	The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified in cash flows from financing activities. The future realization of the reserved deferred tax assets related to these tax benefits associated with the exercise of stock options will result in a credit to additional paid in capital if the related tax deduction reduces taxes payable. The Company has elected the “with and without approach” regarding ordering of windfall tax benefits to determine whether the windfall tax benefit did reduce taxes payable in the current year. Under this approach, the windfall tax benefit would be recognized in additional paid-in-capital only if an incremental tax benefit is realized after considering all other benefits presently available.
	The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASC 505-50.
	Concentrations
	Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.
	The Company’s revenues earned from sale of products and services for the three month period ended December 31, 2014 included an aggregate of 41%, and 12% respectively, from two customers of the Company’s total revenues. These customers accounted for approximately 42%, and 9%, respectively of the Company’s total accounts receivable at December 31, 2014.
	The Company’s revenues earned from sale of products and services for the three month period ended December 31, 2013 included an aggregate of 11% from one customer of the Company’s total revenues.  The customer accounted for approximately 9% of the Company’s total accounts receivable at December 31, 2013.
	Recent Accounting Pronouncements
	In August 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company will adopt the methodologies prescribed by ASU 2014-15 by the date required, and does not anticipate that the adoption of ASU 2014-15 will have a material effect on its condensed consolidated financial position or results of operations.
	In June 2014, the FASB issued Accounting Standards Update 2014-12, “Accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period,” (“ASU 2014-12”) which requires performance-based awards with a performance target that affects vesting and that could be achieved after an employee completes the requisite service period to be accounted for as a performance condition. If performance targets are clearly defined and it is probable that the performance condition will be achieved, stock-based expense should be recognized over the remaining requisite service period. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2015. Early adoption is permitted. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations.
	In May 2014, the FASB issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”) which provides updated, comprehensive revenue recognition guidance for contracts with customers, including a new principles-based five step framework that eliminates much of the industry-specific guidance in current accounting literature. Under ASU 2014-09, revenue recognition is based on a core principle that companies recognize revenue in an amount consistent with the consideration it expects to be entitled to in exchange for the transfer of goods or services. The standards update also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of recognized revenue. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2016. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations.

LIQUIDITY_AND_MANAGEMENTS_PLAN

LIQUIDITY AND MANAGEMENT'S PLAN	3 Months Ended
	Dec. 31, 2014
Liquidity And Management Plan [Abstract]
LIQUIDITY AND MANAGEMENT'S PLAN	NOTE B – LIQUIDITY AND MANAGEMENT’S PLAN
	The Company has recurring net losses, which have resulted in an accumulated deficit of $207,588,916 as of December 31, 2014. The Company incurred a net loss of $7,828,644 and generated negative operating cash flow of $2,355,835 for the three month period ended December 31, 2014. However, the Company also has attained positive working capital of $2,413,855 as of December 31, 2014. At December 31, 2014 the Company had cash and cash equivalents of $2,871,570. The Company’s current capital resources include cash and cash equivalents, accounts receivable and prepaid expenses. Historically, the Company has financed its operations principally from the sale of equity securities. As discussed in Note G, on November 20, 2014 the Company closed its underwritten public offering of common stock and warrants for gross proceeds of $9.3 million before deducting underwriting discounts and offering expenses. The Company utilized approximately $4,091,000 of the gross proceeds to repurchase the remaining Series B Warrants from Crede, as discussed in Note E. The Company raised $2,156,264 in a private placement of common stock and warrants and $1,800,000 in promissory notes during the fiscal year ended September 30, 2014, including $1,000,000 from a related party.
	The Company expects to finance operations primarily through cash flows provided by operating activities provided that it will achieve a sufficient level of future revenues. The Company estimates that its cash and cash equivalents are sufficient to fund operations for the next twelve months. Management is implementing a cost savings plan that is designed to reduce the Company’s cash expenditures for this calendar year.
	The Company will require additional funds to complete the continued development of its products, product manufacturing, and to fund expected additional losses from operations, until revenues are sufficient to cover the Company’s operating expenses. If the Company is unsuccessful in obtaining the necessary additional financing, it will most likely be forced to reduce operations.

ACCOUNTS_PAYABLE_AND_ACCRUED_L

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	3 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	NOTE C – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
	Accounts payable and accrued liabilities at December 31, 2014 and September 30, 2013 are as follows:
		December 31,		September 30,
		2014		2014
		(unaudited)
	Accounts payable	$	885,809	$	1,059,623
	Accrued consulting fees		102,500		102,500
	Accrued salaries payable		205,503		245,761
	Accrued interest payable		—		11,875
	Other accrued expenses		3,200		75,000
	Total	$	1,197,012	$	1,494,759

PROMISSORY_NOTES_PAYABLE

PROMISSORY NOTES PAYABLE	3 Months Ended
	Dec. 31, 2014
Convertible Notes Payable [Abstract]
PROMISSORY NOTES PAYABLE	NOTE D – PROMISSORY NOTES PAYABLE
	On September 11, 2014, the Company issued and sold promissory notes (the “Notes”) in the aggregate principal amount of $1,800,000 and bearing interest at a rate of 12.5% per annum to Dr. James A. Hayward, the Company’s President, Chairman and Chief Executive Officer, in the amount of $1,000,000, and to another individual, in the amount of $800,000, both of whom are “accredited investors” as defined in regulations promulgated under the Securities Act of 1933, as amended (the “Securities Act”).
	The Notes had a ten month maturity. Interest was payable in cash or in shares of common stock at the option of the holders of the Notes. Interest to be paid in shares was to be paid in shares of common stock equal to (i) the amount of interest payable, divided by (ii) the average of the closing prices for the five consecutive trading days immediately preceding the applicable interest date. The Notes may be prepaid in whole or in part, at any time, subject to certain prepayment penalties. Upon an event of default, the Notes and all accrued interest thereon shall automatically convert into common stock at the closing price of the common stock on the date of issuance of the Notes. In the event of a consolidation or merger with another corporation in which the Company does not survive, the Notes shall be paid in full. On November 11, 2014, Dr. Hayward and the other individual agreed to exchange for cancellation their respective notes (including principal and accrued interest thereon) for 315,171 shares of common stock and warrants to purchase 315,171 shares of common stock, in the case of Dr. Hayward, and 252,137 shares of common stock and warrants to purchase 252,137 shares of common stock, in the case of the other individual, at $3.25 per share, the aggregate public offering per share price of common stock and warrants issued in the Company’s underwritten public offering, which closed on November 20, 2014.  The conversion of the promissory notes resulted in a loss on conversion of approximately $981,000, which was recorded on the condensed consolidated statement of operations for the three month period ended December 31, 2014.  The loss was calculated as the difference between the carrying amount of the promissory note and accrued interest on the conversion date compared to the fair value of the common stock and warrant issued as settlement of the Notes.
	Interest expense for these promissory notes was $31,875 for the three month period ended December 31, 2014.

WARRANT_LIABILITY

WARRANT LIABILITY	3 Months Ended
	Dec. 31, 2014
Warrant Liability [Abstract]
WARRANT LIABILITY	NOTE E – WARRANT LIABILITY
	On December 16, 2013, Crede CG III, Ltd (“Crede”) effected the cashless exercise of 178,253 Series A Warrants and 116,667 Series B Warrants. At December 16, 2013 (date of exercise), the Company determined the fair value of the Warrants to be $2,455,042 using the Binomial Lattice model with the following assumptions: fair value of the Company’s common stock $10.80 per share; dividend yield 0%; expected term: 4.55 years; risk free interest rate: 1.55%; expected volatility of: 118.89%; and an exercise price of $14.59. The change in fair value of the warrant liability on the day of exercise amounted to a loss of $1,288,752 and was included in the other income (expense). Upon exercise, the fair value of the Series A Warrants and 116,667 of the Series B Warrants were reclassified to equity. The Series A and Series B Warrants were classified as liabilities due to certain provisions contained in the warrant agreements, which may cause an adjustment to the conversion rate or the number of warrants outstanding.
	The change in fair value of the warrant liability resulted in loss on change in fair value of $2,634,758 for the three month period ended December 31, 2013.
	On October 28, 2014, the Company entered into a warrant repurchase option agreement with Crede, pursuant to which it had the option to purchase between 50% and 100% of the Crede’s Series B Warrant (currently exercisable for 387,621 shares of common stock) at a purchase price of $10.55 per share underlying such Series B Warrant (up to an aggregate purchase price of $4,091,000 for all of the Series B Warrant). On November 21, 2014, the Company exercised its option and repurchased 100% of Crede’s Series B Warrant for an aggregate purchase price of approximately $4,091,000. The change in fair value of the warrant liability on the day of repurchase amounted to a loss of $2,994,540 and was included in other income (expense).

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE F – RELATED PARTY TRANSACTIONS
	As discussed in Note D, on September 11, 2014, the Company issued and sold a promissory note in the aggregate principal amount of $1,000,000 and bearing interest at a rate of 12.5% per annum to Dr. James A. Hayward, the Company’s President, Chairman and Chief Executive Officer. On November 11, 2014, Dr. Hayward agreed to exchange for cancellation of his note (including principal and accrued interest thereon) for 315,171 shares of common stock and warrants to purchase 315,171 shares of common stock, at $3.25 per share, the aggregate public offering price of common stock and warrants issued in the Company’s underwritten public offering which closed on November 20, 2014.
	As discussed in Note G, the Company’s Chief Executive Officer and an affiliated company of a member of the Company’s board of directors participated in the Company’s November 20, 2014 underwritten public offering.

CAPITAL_STOCK

CAPITAL STOCK	3 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
CAPITAL STOCK	NOTE G - CAPITAL STOCK
	On October 24, 2014, the Company filed a Third Certificate of Amendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware that effected a one-for-60 (1:60) reverse stock split of its common stock, par value $.001 per share, and a decrease in its authorized common stock, from 1,350,000,000 to 500,000,000 shares, effective October 29, 2014. All warrant, option, share, and per share information in the condensed consolidated financial statements gives retroactive effect to the one-for-60 reverse stock split that was effected on October 29, 2014. In addition, the Company is authorized to issue 10,000,000 shares of preferred stock with a $0.001 par value per share. As of December 31, 2014 and September 30, 2014, there were 17,361,702 and 13,935,954 shares of common stock issued and outstanding, respectively.
	Common Stock Transactions during the three month period ended December 31, 2014:
	On November 20, 2014, the Company closed its underwritten public offering of 2,800,000 shares of common stock and warrants (“Unit”) to purchase up to an aggregate of 2,800,000 Units for gross proceeds of $9.1 million before deducting underwriting discounts and offering expenses. The Company utilized $4,091,000 of the gross proceeds to repurchase the remaining Series B Warrants from Crede, as discussed in Note E. The public offering price for each Unit was $3.25. The warrants may be exercised for a period of five years and have a per share exercise price of $3.50 per share. In connection with the offering, the Company granted to the underwriters a 45-day option to purchase up to 420,000 additional shares of common stock at $3.24 per share and/or up to 420,000 additional warrants at $0.01 per share to cover over-allotments, if any. The Company’s Chief Executive Officer and an affiliate of a member of the Company’s board of directors participated in this underwritten public offering. The Company’s common stock and warrants are listed on the Nasdaq Capital Market under the symbols “APDN” and “APDNW”, respectively. In addition, the Company agreed to issue to the underwriters’ warrants to purchase 128,800 shares of common stock at an exercise price of $3.73 per share. On December 19, 2014, the Company closed on the underwriters’ exercise of its over-allotment option of 416,850 warrants for gross proceeds of $4,169 and on December 30, 2014 the Company closed on the underwriters’ additional exercise of its over-allotment option of 52,000 shares of common stock for gross proceeds of $168,400.  The total number of common stock and warrants issued under this offering, including the exercise of the over allotment option was 2,852,000 and 3,216,850, respectively.  The gross proceeds to the Company was $9,272,649 and net proceeds after deducting underwriting discounts, offering expenses and the repurchase the remaining Series B Warrants from Crede was approximately $3.69 million.
	See Note D for the common stock and warrants issued in connection with the conversion of the promissory notes.

STOCK_OPTIONS_AND_WARRANTS

STOCK OPTIONS AND WARRANTS	3 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
STOCK OPTIONS AND WARRANTS	NOTE H - STOCK OPTIONS AND WARRANTS
	Warrants
	The following table summarizes the changes in warrants outstanding and the related prices for the shares of common stock issued to non-employees of the Company. These warrants were granted in lieu of cash compensation for services performed or financing expenses in connection with the sale of common stock.
	Transactions involving warrants (see Notes D, E and G) are summarized as follows:
		Number of				Weighted
		Shares				Average Exercise
						Price Per Share
	Balance at October 1, 2014		945,166			$	9.59
	Granted		3,912,958				3.51
	Exercised		(—	)			(—	)
	Cancelled or expired		(387,622	)			(14.06	)
	Balance, December 31, 2014		4,470,502			$	3.88
	Employee Stock Options
	In 2005, the Board of Directors and the holders of a majority of the outstanding shares of common stock approved the 2005 Incentive Stock Plan. In 2007, 2008 and 2012, the Board of Directors and holders of a majority of the outstanding shares of common stock approved various increases in the number of shares of common stock that can be issued as stock awards and stock options thereunder to an aggregate of 5,833,334 shares and the number of shares of common stock that can be covered by awards made to any participant in any calendar year to 833,334 shares.  On January 21, 2015, the Board of Directors approved an amendment to the 2005 Incentive Stock Plan, which is subject to shareholder approval.  The amendment is effective on January 26, 2015 and increases the number of shares of common stock that can be issued as stock awards and stock options thereunder to an aggregate of 8,333,333.  The amendment also extends the Plan’s expiration date to January 25, 2025.
	The 2005 Incentive Stock Plan is designed to retain directors, executives, and selected employees and consultants by rewarding them for making contributions to our success with an award of options to purchase shares of common stock. As of December 31, 2014 a total of 211,252 shares have been issued and options to purchase 4,219,622 shares have been granted under the 2005 Incentive Stock Plan.
	Transactions involving stock options issued to employees are summarized as follows:
		Number of			Weighted Average				Aggregate
		Shares			Exercise				Intrinsic
					Price Per				Value
					Share
	Outstanding at October 1, 2014		2,909,046		$	4.74
	Granted		868,842			2.84
	Exercised		—			—
	Cancelled or expired		—			—
	Outstanding at December 31, 2014		3,777,888		$	4.3
	Vested at December 31, 2014		2,797,486		$	3.95			$	0.76
	Non-vested at December 31, 2014		980,402						$	0.24
	Transactions involving stock options issued to employees and consultants during the three month period ended December 31, 2014 are summarized as follows:
	On November 20, 2014 the Company granted 83,334 options to purchase the Company’s common stock at an exercise price of $2.69 per share for five years to a consultant, which vest immediately.
	On December 22, 2014 the Company granted an aggregate of 610,000 options to purchase the Company’s common stock at an exercise price of $2.86 per share for ten years to employees, including executive officers, with immediate vesting.
	Also on December 22, 2014 the Company granted an aggregate of 175,508 options to purchase the Company’s common stock to non-employee board of director members at an exercise price of $2.86 per share for ten years which, vest in full one year from the grant date.
	On January 21, 2015 the Company granted 1,667 options to purchase the Company’s common stock to an employee at an exercise price of $2.85 per share for five years, with vesting at 25% each anniversary for the next four years.
	The fair value of options granted during the three month period ended December 31, 2014 was determined using the Black Scholes Option Pricing Model with the following weighted average assumptions:
		Three
		Months
		Ended
		December
		31, 2014
	Stock price	$	2.84
	Exercise price	$	2.84
	Dividend yield		—	%
	Volatility		132	%
	Risk free rate		1.58	%
	The Company recorded $1,998,524 and $765,546 as stock compensation expense for the three month periods ended December 31, 2014 and 2013, respectively, for the vesting portion of all options. As of December 31, 2014, unrecorded compensation cost related to non-vested awards was $3,541,616, which is expected to be recognized over a weighted average period of approximately 2.60 years.  The weighted average grant date fair value for options granted during the three month period ended December 31, 2014 was $1,169,277.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE I - COMMITMENTS AND CONTINGENCIES
	Operating Leases
	The Company leases office space under an operating lease in Stony Brook, New York for its corporate headquarters. The lease is for a 30,000 square foot building. The term of the lease commenced on June 15, 2013 and expires on May 31, 2016, with the option to extend the lease for two additional three-year periods. The base rent during the initial lease term is $449,142 per annum. The Company also has operating leases for a laboratory in Huddersfield, England, which is currently inactive and Calverton, New York. The Huddersfield lease is currently on month to month. The Calverton lease was from February 1, 2014 through October 31, 2014, with the option to renew for additional one year periods.  The Calverton lease is currently month to month.  The base rent during the initial lease term is $2,850 per year. Total rent expense for the three month periods ended December 31, 2014 and 2013 was $124,838 and $128,683, respectively.
	Employment Agreement
	The Company has an employment agreement with the Chief Executive Officer. Effective June 21, 2014, the Chief Executive Officer’s annual salary was voluntarily reduced by $50,000. This salary reduction will be accrued and repaid when the Company reaches $3,000,000 in sales for two consecutive quarters or the Company has net income at the end of any fiscal year.  Effective January 1, 2015, the Chief Executive Officer’s annual salary was voluntarily reduced by an additional $50,000.
	Litigation
	From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business.

FAIR_VALUE

FAIR VALUE	3 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
FAIR VALUE	NOTE J - FAIR VALUE
	The carrying value of cash, accounts receivable, accounts payable and accrued expenses approximate estimated fair values because of their short maturities.
	The carrying value of the warrant liability is determined using the Binomial Lattice option pricing model as described in Note A. Certain assumptions used in the calculation of the warrant liability represent level-3 unobservable inputs. The Company did not have any assets or liabilities categorized as Level 1 or 2 as of December 31, 2014.
	The following table summarizes the activity of Level 3 inputs measured on a recurring basis:
	Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)	Three Month Periods Ended
		December 31,
		2014			2013
	Balance at October 1, 2014 and 2013	$	1,096,412		$	2,643,449
	Issuance of Series A and B Warrants		—			—
	Adjustment resulting from change in fair value (a)		2,994,540			2,634,758
	Removal of warrant upon repurchase		(4,090,952	)
	Reclassification to equity upon exercise		—			(2,455,042	)
	Balance at December 31,	$	—		$	2,823,165
	(a) Adjustment resulting from change in fair value is the amount of total gains or losses for the period attributable to the change in unrealized gains or losses relating to warrant liabilities held at the reporting date and realized gains or losses at the date of exercise. The gain or loss is recorded in change in fair value of warrant liability in the accompanying condensed consolidated statements of operations.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE K – SUBSEQUENT EVENTS
	On February 9, 2015, Karol Kain Gray submitted her resignation as Chief Financial Officer of the Company effective February 15, 2015 to pursue other opportunities.
	On February 9, 2015, Beth Jantzen, CPA, the Company’s Controller was appointed as Chief Financial Officer of the Company, effective February 15, 2015. Ms. Jantzen has held the position of Controller since May 2013.  Prior to joining the Company Ms. Jantzen was a senior manager at Marcum LLP, the Company’s independent registered accounting firm since June 9, 2014, where she managed multiple engagements and specialized in SEC policies, practices and procedures, including Sarbanes-Oxley compliance.
	Pursuant to an offer letter, Ms. Jantzen will be an at-will employee and will be paid an annual starting salary of $225,000. In addition, she will be granted a ten year option pursuant to the Company’s 2005 Incentive Stock Plan to purchase up to 30,000 shares of the Company’s common stock, $.001 par value, at the fair market value on the date of grant, vesting in four equal annual increments beginning on the first anniversary of the date of grant. This grant is subject to shareholder approval of the amendment and extension of the 2005 Incentive Stock Plan, as discussed above in Note H.
	In connection with her resignation, Ms. Gray executed a Separation Agreement, dated February 9, 2015, with the Company which provides her with the immediate vesting of all current unvested stock options as well as five years to exercise her stock options.  Ms. Gray will also remain as a financial consultant to the Company.

SUMMARY_OF_ACCOUNTING_POLICIES1

SUMMARY OF ACCOUNTING POLICIES (Policies)	3 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation
	On September 16, 2002, Applied DNA Sciences, Inc. (the “Company”) was incorporated under the laws of the State of Nevada. Effective December 17, 2008, the Company reincorporated from the State of Nevada to the State of Delaware. The Company is principally devoted to developing DNA embedded biotechnology security solutions in the United States and Europe. To date, the Company has had a limited operating history, and as a result, its operations have produced limited recurring revenues from its services and products; it has incurred expenses and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a biotechnology company. For the period from inception through December 31, 2014, the Company has accumulated losses of $207,588,916.
	The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, APDN (B.V.I.) Inc. and Applied DNA Sciences Europe Limited, which currently have no operations or activity. Significant inter-company transactions and balances have been eliminated in consolidation.
Revenue Recognition	Revenue Recognition
	The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered or services provided and the collectability of those amounts. Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered, service has not been provided, or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered, the service has been provided, or no refund will be required. At December 31, 2014 and September 30, 2014, the Company recorded deferred revenue of $524,361 and $583,362, respectively.
	Revenue arrangements with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered component has stand-alone value to the customer. Consideration received is allocated among the separate units of accounting based on their respective selling prices. The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party is available. The applicable revenue recognition criteria are then applied to each of the units.
	Revenue for government contract awards, which supports the Company’s development efforts on specific projects, is recognized as milestones are achieved as per the contract. The Company recognized revenue of approximately $449,647 and $25,000 from these contract awards during the three month periods ended December 31, 2014 and 2013, respectively.
Net Loss Per Share	Net Loss Per Share
	The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share. Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants.
	For the three month periods ended December 31, 2014 and 2013, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.
	Securities that could potentially dilute basic net income per share in the future that were not included in the computation of diluted net loss per share because to do so would have been antidilutive for the three month periods ended December 31, 2014 and 2013 are as follows:
		2014		2013
	Warrants		4,470,502		688,969
	Employee options		3,777,888		3,166,416
			8,248,390		3,855,385
Stock Based Compensation	Stock Based Compensation
	The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified in cash flows from financing activities. The future realization of the reserved deferred tax assets related to these tax benefits associated with the exercise of stock options will result in a credit to additional paid in capital if the related tax deduction reduces taxes payable. The Company has elected the “with and without approach” regarding ordering of windfall tax benefits to determine whether the windfall tax benefit did reduce taxes payable in the current year. Under this approach, the windfall tax benefit would be recognized in additional paid-in-capital only if an incremental tax benefit is realized after considering all other benefits presently available.
	The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASC 505-50.
Concentrations	Concentrations
	Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.
	The Company’s revenues earned from sale of products and services for the three month period ended December 31, 2014 included an aggregate of 41%, and 12% respectively, from two customers of the Company’s total revenues. These customers accounted for approximately 42%, and 9%, respectively of the Company’s total accounts receivable at December 31, 2014.
	The Company’s revenues earned from sale of products and services for the three month period ended December 31, 2013 included an aggregate of 11% from one customer of the Company’s total revenues.  The customer accounted for approximately 9% of the Company’s total accounts receivable at December 31, 2013.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In August 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company will adopt the methodologies prescribed by ASU 2014-15 by the date required, and does not anticipate that the adoption of ASU 2014-15 will have a material effect on its condensed consolidated financial position or results of operations.
	In June 2014, the FASB issued Accounting Standards Update 2014-12, “Accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period,” (“ASU 2014-12”) which requires performance-based awards with a performance target that affects vesting and that could be achieved after an employee completes the requisite service period to be accounted for as a performance condition. If performance targets are clearly defined and it is probable that the performance condition will be achieved, stock-based expense should be recognized over the remaining requisite service period. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2015. Early adoption is permitted. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations.
	In May 2014, the FASB issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”) which provides updated, comprehensive revenue recognition guidance for contracts with customers, including a new principles-based five step framework that eliminates much of the industry-specific guidance in current accounting literature. Under ASU 2014-09, revenue recognition is based on a core principle that companies recognize revenue in an amount consistent with the consideration it expects to be entitled to in exchange for the transfer of goods or services. The standards update also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of recognized revenue. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2016. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations.

SUMMARY_OF_ACCOUNTING_POLICIES2

SUMMARY OF ACCOUNTING POLICIES (Tables)	3 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of stock issuances under options and warrants that could have a dilutive effect on the shares outstanding		2014		2013
	Warrants		4,470,502		688,969
	Employee options		3,777,888		3,166,416
			8,248,390		3,855,385

ACCOUNTS_PAYABLE_AND_ACCRUED_L1

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	3 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of accounts payable and accrued liabilities
		December 31,		September 30,
		2014		2014
		(unaudited)
	Accounts payable	$	885,809	$	1,059,623
	Accrued consulting fees		102,500		102,500
	Accrued salaries payable		205,503		245,761
	Accrued interest payable		—		11,875
	Other accrued expenses		3,200		75,000
	Total	$	1,197,012	$	1,494,759

STOCK_OPTIONS_AND_WARRANTS_Tab

STOCK OPTIONS AND WARRANTS (Tables)	3 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Schedule of transactions involving warrants
		Number of				Weighted
		Shares				Average Exercise
						Price Per Share
	Balance at October 1, 2014		945,166			$	9.59
	Granted		3,912,958				3.51
	Exercised		(—	)			(—	)
	Cancelled or expired		(387,622	)			(14.06	)
	Balance, December 31, 2014		4,470,502			$	3.88
Schedule of summary of transactions involving stock options issued to employees
		Number of			Weighted Average				Aggregate
		Shares			Exercise				Intrinsic
					Price Per				Value
					Share
	Outstanding at October 1, 2014		2,909,046		$	4.74
	Granted		868,842			2.84
	Exercised		—			—
	Cancelled or expired		—			—
	Outstanding at December 31, 2014		3,777,888		$	4.3
	Vested at December 31, 2014		2,797,486		$	3.95			$	0.76
	Non-vested at December 31, 2014		980,402						$	0.24
Schedule of fair value of options granted
		Three
		Months
		Ended
		December
		31, 2014
	Stock price	$	2.84
	Exercise price	$	2.84
	Dividend yield		—	%
	Volatility		132	%
	Risk free rate		1.58	%

FAIR_VALUE_Tables

FAIR VALUE (Tables)	3 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Schedule of fair value measurements of common stock warrants using significant unobservable inputs (Level 3)	Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)	Three Month Periods Ended
		December 31,
		2014			2013
	Balance at October 1, 2014 and 2013	$	1,096,412		$	2,643,449
	Issuance of Series A and B Warrants		—			—
	Adjustment resulting from change in fair value (a)		2,994,540			2,634,758
	Removal of warrant upon repurchase		(4,090,952	)
	Reclassification to equity upon exercise		—			(2,455,042	)
	Balance at December 31,	$	—		$	2,823,165

SUMMARY_OF_ACCOUNTING_POLICIES3

SUMMARY OF ACCOUNTING POLICIES - Summary of potential stock issuances under various options, and warrants (Details)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Warrants	4,470,502	688,969
Employee options	3,777,888	3,166,416
Total number of potential stock issuances under various options, and warrants	8,248,390	3,855,385

SUMMARY_OF_ACCOUNTING_POLICIES4

SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) (USD $)	1 Months Ended	3 Months Ended
	Oct. 24, 2014	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2014
Accounting Policies [Abstract]
Reverse stock split	one-for-60 (1:60)
Accumulated losses		($207,588,916)		($199,760,272)
Deferred revenue		524,361		583,362
Revenue for government contract awards		$449,647	$25,000

SUMMARY_OF_ACCOUNTING_POLICIES5

SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1) (Customer Concentration Risk)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
	Customer	Customer
Total Revenue
Concentration Risk [Line Items]
Number of customers	2	1
Total Revenue | Customer One
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable	41.00%	11.00%
Total Revenue | Customer Two
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable	12.00%
Accounts Receivable
Concentration Risk [Line Items]
Number of customers	2	1
Accounts Receivable | Customer One
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable	42.00%	9.00%
Accounts Receivable | Customer Two
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable	9.00%

LIQUIDITY_AND_MANAGEMENTS_PLAN1

LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) (USD $)	1 Months Ended	3 Months Ended		12 Months Ended
	Nov. 20, 2014	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2013
Liquidity And Management Plan [Abstract]
Accumulated deficit		($207,588,916)		($199,760,272)
Net loss		-7,828,644	-6,291,650
Operating cash flow		-2,355,835	-2,066,448
Working capital		2,413,855
Cash and cash equivalents		2,871,570	4,199,343	1,393,132	6,360,301
Gross proceeds from underwritten public offering of common stock and warrants	9,300,000
Gross proceeds to repurchase remaining Series B Warrants	4,091,000
Proceeds from issuance of private placement of common stock and warrants				2,156,264
Proceeds from promissory notes				1,800,000
Proceeds from promissory notes from related party				$1,000,000

ACCOUNTS_PAYABLE_AND_ACCRUED_L2

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) (USD $)	Dec. 31, 2014	Sep. 30, 2014
Payables and Accruals [Abstract]
Accounts payable	$885,809	$1,059,623
Accrued consulting fees	102,500	102,500
Accrued salaries payable	205,503	245,761
Accrued interest payable		11,875
Other accrued expenses	3,200	75,000
Total	$1,197,012	$1,494,759

PROMISSORY_NOTES_PAYABLE_Detai

PROMISSORY NOTES PAYABLE (Detail Textuals) (USD $)	3 Months Ended	0 Months Ended
	Dec. 31, 2014	Nov. 11, 2014	Nov. 20, 2014	Sep. 30, 2014	Sep. 11, 2014
Short-term Debt [Line Items]
Promissory note issued to related party (in dollars)				$1,000,000
Promissory notes maturity term	10 months
Debt instrument, convertible, threshold consecutive trading days	5 days
Conversion price of convertible promissory note converted into common stock (in dollars per share)			$3.25
Loss on conversion of promissory notes	980,842
Promissory notes
Short-term Debt [Line Items]
Promissory note issued to related party (in dollars)					1,800,000
Interest rate on promissory note					12.50%
Loss on conversion of promissory notes	981,000
Interest expense	31,875
Promissory notes | James A. Hayward
Short-term Debt [Line Items]
Promissory note issued to related party (in dollars)					1,000,000
Interest rate on promissory note					12.50%
Common stock issued in settlement of convertible debentures and interest		315,171
Number of shares issued in settlement of convertible notes and accrued interest		315,171
Conversion price of convertible promissory note converted into common stock (in dollars per share)		$3.25
Promissory notes | Another individual
Short-term Debt [Line Items]
Promissory note issued to related party (in dollars)					$800,000
Common stock issued in settlement of convertible debentures and interest		252,137
Number of shares issued in settlement of convertible notes and accrued interest		252,137
Conversion price of convertible promissory note converted into common stock (in dollars per share)		$3.25

WARRANT_LIABILITY_Detail_Textu

WARRANT LIABILITY (Detail Textuals) (USD $)	3 Months Ended		0 Months Ended	1 Months Ended	2 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 16, 2013	Oct. 28, 2014	Nov. 21, 2014
Class of Warrant or Right [Line Items]
Cashless exercise of warrant
Fair value of common stock	$2.84
Loss on change in fair value of warrant liability	($2,994,540)	($2,634,758)
Crede CG III, Ltd | Warrants
Class of Warrant or Right [Line Items]
Fair value of warrants			2,455,042
Method used for determining allocated fair value of the Warrants			Binomial Lattice model
Fair value of common stock			$10.80
Dividend yield			0.00%
Expected terms			4 years 6 months 18 days
Risk free interest rate			1.55%
Expected volatility			118.89%
Expected price at which holders exercise Warrants			$14.59
Loss on change in fair value of warrant liability			-1,288,752
Crede CG III, Ltd | Series A Warrants
Class of Warrant or Right [Line Items]
Cashless exercise of warrant			178,253
Crede CG III, Ltd | Series B Warrants
Class of Warrant or Right [Line Items]
Cashless exercise of warrant			116,667
Crede CG III, Ltd | Series B Warrants | Warrant repurchase option agreement
Class of Warrant or Right [Line Items]
Cashless exercise of warrant				387,621
Expected price at which holders exercise Warrants				$10.55
Percentage of option to purchase warrant					100.00%
Aggregate purchase price of warrant exercise				$4,091,000	$4,091,000
Crede CG III, Ltd | Series B Warrants | Warrant repurchase option agreement | Minimum
Class of Warrant or Right [Line Items]
Percentage of option to purchase warrant				50.00%
Crede CG III, Ltd | Series B Warrants | Warrant repurchase option agreement | Maximum
Class of Warrant or Right [Line Items]
Percentage of option to purchase warrant				100.00%

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Detail Textuals) (USD $)	0 Months Ended
	Nov. 11, 2014	Nov. 20, 2014	Sep. 30, 2014	Sep. 11, 2014
Short-term Debt [Line Items]
Promissory note issued to related party (in dollars)			$1,000,000
Conversion price of convertible promissory note converted into common stock (in dollars per share)		$3.25
Promissory notes
Short-term Debt [Line Items]
Promissory note issued to related party (in dollars)				1,800,000
Interest rate on promissory note				12.50%
Promissory notes | James A. Hayward
Short-term Debt [Line Items]
Promissory note issued to related party (in dollars)				1,000,000
Interest rate on promissory note				12.50%
Common stock issued in settlement of convertible debentures and interest	315,171
Number of shares issued in settlement of convertible notes and accrued interest	315,171
Conversion price of convertible promissory note converted into common stock (in dollars per share)	$3.25
Promissory notes | Another individual
Short-term Debt [Line Items]
Promissory note issued to related party (in dollars)				$800,000
Common stock issued in settlement of convertible debentures and interest	252,137
Number of shares issued in settlement of convertible notes and accrued interest	252,137
Conversion price of convertible promissory note converted into common stock (in dollars per share)	$3.25

CAPITAL_STOCK_Detail_Textuals

CAPITAL STOCK (Detail Textuals) (USD $)	1 Months Ended
	Oct. 24, 2014	Dec. 31, 2014	Sep. 30, 2014
Stockholders' Equity Note [Abstract]
Reverse stock split	one-for-60 (1:60)
Common stock, par value (in dollars per share)		$0.00	$0.00
Common stock, shares authorized		500,000,000	1,350,000,000
Preferred stock, shares authorized		10,000,000	10,000,000
Preferred stock, par value (in dollars per share)		$0.00	$0.00
Common stock, shares issued		17,361,702	13,935,954
Common stock, shares outstanding		17,361,702	13,935,954

CAPITAL_STOCK_Detail_Textuals_

CAPITAL STOCK (Detail Textuals 1) (USD $)	1 Months Ended			3 Months Ended
	Dec. 19, 2014	Dec. 30, 2014	Nov. 20, 2014	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Underwritten public offering of common stock closed			2,800,000
Number of common stock called by warrants			2,800,000
Gross proceeds from underwritten public offering of common stock and warrants			$9,300,000
Gross proceeds to repurchase remaining Series B Warrants			4,091,000
Conversion price of convertible promissory note converted into common stock (in dollars per share)			$3.25
Period of warrant exercised			5 years
Exercise price of warrants			$3.50
Number of days option given to underwriters			45 days
Additional common stock purchase limit given to underwriters			420,000
Additional common stock per share purchase limit given to underwriters			$3.24
Additional warrants purchase limit given to underwriters			420,000
Additional per share warrants purchase limit given to underwriters			$0.01
Additional number of common stock called by warrants			128,800
Exercise price of warrants which company agreed to issue to the underwriters			$3.73
Warrant closed on the underwriters exercise of over-allotment option	416,850
Gross proceeds from closed on underwriters exercise of over-allotment option	4,169
Common stock closed on underwriters additional exercise of over-allotment option		52,000
Gross proceeds from closed on underwriters additional exercise of over-allotment option		168,400
Number of common stock including the exercise of over allotment option			2,852,000
Number of warrant issued including the exercise of over allotment option			3,216,850
Gross proceeds from sale of common stock and warrants			9,272,649
Net proceeds from sale of common stock and warrants			$3,690,000	$7,956,050

STOCK_OPTIONS_AND_WARRANTS_Tra

STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details) (USD $)	3 Months Ended
	Dec. 31, 2014
Number of Shares
Balance at October 1, 2014	945,166
Granted	3,912,958
Exercised
Cancelled or expired	-387,622
Balance, December 31, 2014	4,470,502
Weighted Average Exercise Price Per Share
Balance at October 1, 2014	$9.59
Granted	$3.51
Exercised
Cancelled or expired	($14.06)
Balance, December 31, 2014	$3.88

STOCK_OPTIONS_AND_WARRANTS_Tra1

STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees (Details 1) (Employee Stock Options, Incentive Stock Plan 2005, USD $)	3 Months Ended
	Dec. 31, 2014
Employee Stock Options | Incentive Stock Plan 2005
Number of Shares
Outstanding at October 1, 2014	2,909,046
Granted	868,842
Exercised
Cancelled or expired
Outstanding at December 31, 2014	3,777,888
Vested at December 31, 2014	2,797,486
Non-vested at December 31, 2014	980,402
Weighted Average Exercise Price Per Share
Outstanding at October 1, 2014	$4.74
Granted	$2.84
Exercised
Cancelled or expired
Outstanding at December 31, 2014	$4.30
Vested at December 31, 2014	$3.95
Aggregate Intrinsic Value, Vested at December 31, 2014	$0.76
Aggregate Intrinsic Value, Non-vested at December 31, 2014	$0.24

STOCK_OPTIONS_AND_WARRANTS_Sum

STOCK OPTIONS AND WARRANTS - Summary of value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details) (USD $)	3 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Stock price	$2.84
Exercise price	$2.84
Dividend yield
Volatility	132.00%
Risk free rate	1.58%

STOCK_OPTIONS_AND_WARRANTS_Emp

STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals) (Employee Stock Options, Incentive Stock Plan 2005)	3 Months Ended
	Dec. 31, 2014	Jan. 21, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of common stock that can be issued as stock awards and stock option	5,833,334
Number of common stock shares that can be covered by awards made to any participant per period	833,334
Number of shares issued	211,252
Options to purchase shares under the 2005 Incentive Stock Plan	4,219,622
Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of common stock that can be issued as stock awards and stock option		8,333,333

STOCK_OPTIONS_AND_WARRANTS_Emp1

STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals 1) (USD $)	3 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jan. 21, 2015	Nov. 20, 2014	Dec. 22, 2014
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Stock-based compensation expense	$1,998,524	$765,546
Allocated share-based compensation expense		1,169,277
Unrecorded compensation cost related to non-vested awards	$3,541,616
Weighted average period of non-vested awards options		2 years 6 months
Employee Stock Options | Incentive Stock Plan 2005
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number of options granted	868,842
Exercise price per share of options granted	$2.84
Number of options vested	2,797,486
Employee Stock Options | Vesting on each anniversary for next four years | Employee | Subsequent Event
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number of options granted			1,667
Exercise price per share of options granted			$2.85
Vesting period of options issued			5 years
Percentage of vesting in each year			25.00%
Employee Stock Options | Immediate vesting | Consultant
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number of options granted				83,334
Exercise price per share of options granted				$2.69
Vesting period of options issued				5 years
Employee Stock Options | Immediate vesting | Employees, including executive officers
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number of options granted					610,000
Exercise price per share of options granted					$2.86
Vesting period of options issued					10 years
Employee Stock Options | Vest in full one year from grant date | Non-employee board of director members
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number of options granted					175,508
Exercise price per share of options granted					$2.86
Vesting period of options issued					10 years

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Detail Textuals) (USD $)	0 Months Ended	3 Months Ended		9 Months Ended
	Jun. 15, 2013	Dec. 31, 2014	Dec. 31, 2013	Oct. 31, 2014	Jun. 21, 2014	Jan. 01, 2015
	sqft
Commitments And Contingencies [Line Items]
Area of property under operating lease	30,000
Extended operating lease for two additional period	3 years
Base rent during initial lease term per annum	$449,142			$2,850
Total lease rental expenses		124,838	128,683
Chief Executive Officer | Employment Agreement
Commitments And Contingencies [Line Items]
Reduced amount of salary					50,000
Threshold amount of sale for two consecutive quarters					3,000,000
Chief Executive Officer | Employment Agreement | Subsequent Event
Commitments And Contingencies [Line Items]
Reduced amount of salary						$50,000

FAIR_VALUE_Fair_Value_Measurem

FAIR VALUE - Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3) (Details) (Common Stock Warrants, USD $)	3 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Common Stock Warrants
Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)
Balance at October 1, 2014 and 2013	$1,096,412		$2,643,449
Issuance of Series A and B Warrants
Adjustment resulting from change in fair value	2,994,540	[1]	2,634,758	[1]
Removal of warrant upon repurchase	-4,090,952
Reclassification to equity upon exercise			-2,455,042
Balance at December 31,			$2,823,165
[1]	Adjustment resulting from change in fair value is the amount of total gains or losses for the period attributable to the change in unrealized gains or losses relating to warrant liabilities held at the reporting date and realized gains or losses at the date of exercise. The gain or loss is recorded in change in fair value of warrant liability in the accompanying condensed consolidated statements of operations.

SUBSEQUENT_EVENTS_Detail_Textu

SUBSEQUENT EVENTS (Detail Textuals) (USD $)	3 Months Ended	1 Months Ended
	Dec. 31, 2014	Feb. 09, 2015
Employee Stock Options | Incentive Stock Plan 2005
Subsequent Event [Line Items]
Number of options granted	868,842
Exercise price per share of options granted	$2.84
Subsequent Event | Ms. Jantzen
Subsequent Event [Line Items]
Annual starting salary		$225,000
Subsequent Event | Employee Stock Options | Vesting in four equal annual increments | Ms. Jantzen | Incentive Stock Plan 2005
Subsequent Event [Line Items]
Vesting period of options issued		10 years
Number of options granted		30,000
Exercise price per share of options granted		$0.00